Diversifying ADC Payloads as Warheads for Overcoming Tumor Resistance, with Optimized Efficacy, Potency, & Differentiated Mechanisms of Action
As the ADC field becomes increasingly crowded with TOPO-1 and tubulin-based payloads, the pressure is on to identify differentiated mechanisms that can overcome resistance, improve therapeutic index, and deliver meaningful clinical advantage. Recent acquisitions, partnerships, and investment activity have highlighted growing industry demand for next-generation payload innovation, but significant challenges remain around potency, safety, translation, and clinical success.
The 3rd ADC Payload Summit is the only dedicated forum focused exclusively on payload innovation, bringing together 70+ leaders across payload chemistry, discovery biology, translational science, and R&D to tackle these challenges head-on. Through deep-dive workshops, case studies, panel discussions, and the Brand-New Curated Matchmaking Roundtables, attendees will explore novel payload classes, dual-payload strategies, resistance mechanisms, translational modelling, and emerging approaches beyond traditional cytotoxicity.
It’s exciting to see and learn about new and emerging ADC payloads!
Despite a long history of ADCs, the payloads at the clinical stage are mostly limited to a small number of cytotoxic molecules. Recently we have seen rapid expansion of payload classes used in preclinical ADC research. Research groups sharing experiences and learnings from each program will greatly benefit the field as we continue to explore various payload mechanism of action
This was a highly specialized meeting which focused on the latest developments of payloads targeting immunology-oncology space.
Explore the Full Event Guide:
- 3 Days of Deep-Dive Content Exploring Novel Payload Mechanisms, Resistance Biology & Next-Generation ADC Design
- 70+ ADC Leaders Across Payload Chemistry, Biology, Discovery & Translational R&D
- 2 Interactive Pre-Conference Workshops on Dual Payload ADCs & Expanding the Therapeutic Window
- Brand-New Curated Matchmaking Roundtables Connecting You with Potential Partners, Collaborators & Solution Providers
- Exclusive Case Studies, Panels & Discussions on Non-Cytotoxic Payloads, Multi-Payload Strategies & Overcoming TOPO-1/Tubulin Resistance
Expert Speaker Faculty
Official Partners:
Attending Companies Include
Explore the Agenda
Discover the complete agenda featuring novel payload mechanisms, dual-payload ADCs, resistance biology, therapeutic index optimisation, and the industry leaders redefining ADC payload innovation.
Partner With the ADC Payload Community
Position your organization alongside 70+ senior payload, chemistry, biology, and translational R&D leaders actively seeking technologies, expertise, and collaborations to accelerate next-generation ADC development.
Join 70+ ADC Payload Leaders
Connect with scientists and decision-makers from biopharma and biotech companies tackling the industry's biggest challenges, from overcoming resistance and diversifying payloads to improving clinical translation.